



# Characterization of the transcriptional response of *Candida parapsilosis* to the antifungal peptide MAF-1A

Rong Cheng<sup>1</sup>, Wei Li<sup>2</sup>, Klarke M. Sample<sup>3,4</sup>, Qiang Xu<sup>3,4</sup>, Lin Liu<sup>4,5</sup>, Fuxun Yu<sup>3,4</sup>, Yingjie Nie<sup>3,4</sup>, Xiangyan Zhang<sup>4,5</sup> and Zhenhua Luo<sup>3,4</sup>

<sup>1</sup> Guizhou University School of Medicine, Guiyang, China

<sup>2</sup> Department of Cardiovascular Medicine, Affiliated Hospital of Guizhou Medical University, Guiyang, China

<sup>3</sup> Department of Central Lab, Guizhou Provincial People's Hospital, Guiyang, China

<sup>4</sup> NHC Key Laboratory of Pulmonary Immune-related Diseases, Guizhou Provincial People's Hospital, Guiyang, China

<sup>5</sup> Department of Respiratory and Critical Care Medicine, Guizhou Provincial People's Hospital, Guiyang, China

## ABSTRACT

*Candida parapsilosis* is a major fungal pathogen that leads to sepsis. New and more effective antifungal agents are required due to the emergence of resistant fungal strains. MAF-1A is a cationic antifungal peptide isolated from *Musca domestica* that is effective against a variety of *Candida* species. However, the mechanism(s) of its antifungal activity remains undefined. Here, we used RNA-seq to identify differentially expressed genes (DEGs) in *Candida parapsilosis* following MAF-1A exposure. The early (6 h) response included 1,122 upregulated and 1,065 downregulated genes. Late (18 h) responses were associated with the increased expression of 101 genes and the decreased expression of 151 genes. Upon MAF-1A treatment for 18 h, 42 genes were upregulated and 25 genes were downregulated. KEGG enrichment showed that the DEGs in response to MAF-1A were mainly involved in amino acid synthesis and metabolism, oxidative phosphorylation, sterol synthesis, and apoptosis. These results indicate that MAF-1A exerts antifungal activity through interference with *Candida parapsilosis* cell membrane integrity and organelle function. This provides new insight into the interaction between *Candida parapsilosis* and this antimicrobial peptide and serves as a reference for future *Candida parapsilosis* therapies.

Submitted 10 February 2020

Accepted 29 July 2020

Published 7 September 2020

Corresponding authors

Xiangyan Zhang,

[zxiangyan12@sina.com](mailto:zxiangyan12@sina.com)

Zhenhua Luo, [luo8300@sina.com](mailto:luo8300@sina.com)

Academic editor

Timothy Read

Additional Information and  
Declarations can be found on  
page 14

DOI 10.7717/peerj.9767

© Copyright  
2020 Cheng et al.

Distributed under  
Creative Commons CC-BY 4.0

OPEN ACCESS

**Subjects** Bioinformatics, Genomics, Microbiology, Molecular Biology, Mycology

**Keywords** Antimicrobial peptide, Antifungal, MAF-1A, *Candida parapsilosis*, Transcriptional response, RNA-seq

## INTRODUCTION

Immunosuppressed patients are at a high risk of hospital-acquired fungal infections. *Candida albicans* (*C. albicans*) is the most common pathogen of *Candida* species, its dominance has decreased as the incidence of non-*albicans* *Candida* (NAC) species have increased (*Vieira de Melo et al., 2019*). Over the last two decades, epidemiological studies of fungal pathogens have shown that NAC has surpassed *C. albicans* as the most prevalent cause of invasive *Candida* (*Sular et al., 2018*). New anti-NAC treatment regimens are therefore urgently required.

Amongst NAC infections, *Candida parapsilosis* (*C. parapsilosis*) is particularly problematic due to its propensity to form biofilms on central venous catheters and other medically implanted devices (Fais et al., 2017; Vieira de Melo et al., 2019). Additionally, patients in the intensive care unit (ICU) who have undergone total parenteral nutrition are highly susceptible to *C. parapsilosis* infection, including undernourished children and neonates of low-birth-weights. Recent epidemiological studies have shown that *C. parapsilosis* is the second most commonly isolated species following only *C. albicans* in southern Europe, some regions of Asia, and Latin America (Toth et al., 2019). When immunosuppressed patients are exposed to *C. parapsilosis*, the rate of infection is high. The biological characteristics of infection, include toxicity, immune regulation, and drug resistance are in contrast with those of *C. albicans* (Toth et al., 2019). These interspecies specificities affect recognition by the host, clearance, and antifungal drug efficacy.

*Candida* pathogens have developed varying degrees of drug resistance, with some representing a serious threat to human health (Robbins, Caplan & Cowen, 2017). The currently available antifungal agents inhibit cell wall synthesis (echinocandins), destroy cell membrane components (azoles), or bind to ergosterol and perforate the cell membrane (amphotericin B). With the widespread use of antifungal drugs, the presence of drug resistance-related genes has increased. Antimicrobial peptides (AMPs) form a key arm of the innate immune response of a variety of organisms including plants, insects, and humans (Moravej et al., 2018). It is uncommon for microbial infections to be resistant to AMPs which are an emerging source of novel antifungal drugs (Ghosh et al., 2019; Nuti et al., 2017; Patocka et al., 2018), making these molecules a potential alternative to fungemia therapies.

AMPs can exhibit both cationic and amphiphilic properties. Cationic AMPs are amphipathic permitting their interaction with negatively charged cell membranes, leading to cell membrane disruption and cell death (Kobbi et al., 2018). AMPs are diverse with respect to length (20–100 amino acids), sequence and structure, and are produced by almost all organisms. Filamentous fungi produce a wide spectrum of AMPs that serve as defense and/or host signaling molecules. *Penicillium chrysogenum* secretes PAF and PAFB that possess complex tertiary structures and activity centers. PAF and PAFB are produced as 92 amino acid preproteins that are active against a variety of pathogenic fungi, bacteria, and viruses (Huber et al., 2020). Insects are extremely resistant to microbial infections, which are an important source of AMPs. Insect AMPs are smaller (between 12 and 50 amino acids) with secondary structures formed predominantly of  $\alpha$ -helices and  $\beta$ -sheets. Whilst membrane damage is the canonical mechanism through which AMPs act, other mechanisms exist. AMPs have specific subcellular targets, including the inhibition of DNA synthesis, RNA synthesis, protein synthesis, and cell wall integrity (Guilhelmelli et al., 2013; Li et al., 2016). However, their mechanism(s) of action at the molecular level remain unclear. The *Musca domestica* antifungal peptide-1 (MAF-1) is a novel cationic AMP isolated from the instar larvae of houseflies (Fu, Wu & Guo, 2009). We previously cloned the full-length MAF-1 gene and derived 26 amino acid MAF-1A peptides from the MAF-1 structural domain. Despite the established antifungal effects of MAF-1A, the molecular mechanism(s) governing its activity remain largely undefined (Zhou et al., 2016).

In recent years, the development of high throughput sequencing technologies has facilitated research on both antimicrobial drug function and drug-resistance. For example, HAC1 (CPAR2\_103720) is a key mediator of endoplasmic reticulum stress in *C. parapsilosis* identified through RNA-seq ([Iracane et al., 2018](#)). In our previous studies, we showed that MAF-1A inhibits *C. albicans* through its effects on the cell wall, plasma membrane, protein synthesis, and energy metabolism ([Wang et al., 2017](#)). However, the mechanism(s) through which *C. albicans* responds to MAF-1A were not fully defined. Here, we have expanded our knowledge on how MAF-1A acts on *C. parapsilosis* and investigated differences in the responses of *C. albicans* and *C. parapsilosis* to MAF-1A treatment. RNA-seq was used to investigate changes in gene expression at early (6 h) and late (18 h) time points, according to time-kill curves of *C. parapsilosis* growth.

## MATERIALS AND METHODS

### Strains and growth conditions

Transcriptional profiling was performed on the *C. parapsilosis* reference strain ATCC22019. The strain was preserved in goat blood and stored at  $-80^{\circ}\text{C}$ . *C. parapsilosis* was streaked on Sabouraud Dextrose Agar (SDA) plates (Sangon, Shanghai, China) at  $35^{\circ}\text{C}$  as described by [Lis et al. \(2010\)](#). MAF-1A treatments were performed in Sabouraud Dextrose Broth (SDB) (Sangon, Shanghai, China).

### Peptide synthesis

MAF-1A was synthesized by Sangon Biotech (Shanghai, Shanghai, China) as a linear peptide of 26 amino acids: KKFKETADKLIESAKQQLES LAKEMK. Analytical high-performance liquid chromatography (HPLC) was used to confirm purity  $\geq 95\%$ . The peptide was dissolved in sterile ultrapure water at 5 mg/mL and stored at  $-20^{\circ}\text{C}$ .

### Minimum inhibitory concentration (MIC) and time-kill curves

Antifungal assays were performed as per the requirements of the Clinical and Laboratory Standards Institute (CLSI) M27-A3. Briefly, cultures were grown for 24 h at  $35^{\circ}\text{C}$  and resuspended in SDB. Concentrations were adjusted to approximately  $0.5 \times 10^3$ – $2.5 \times 10^3$  CFU/mL and 100  $\mu\text{l}$  of the suspension was added to each well of 96-well polypropylene microplates (NEST, Wuxi, China). MAF-1A was added at concentration ranging from 0.1 mg/mL to 1.2 mg/mL. All experiments were performed in triplicates. After incubation at  $35^{\circ}\text{C}$  for 24 h, absorbances were measured at 492 nm on a Microplate Reader (BioTek Synergy H1, Vermont, USA). MIC was defined as the lowest drug concentration showing 80% growth inhibition compared to the drug-free controls. The following formulas were used ([Li et al., 2008](#)):

(1) Percentage Fungal Growth = (Treatment Well A Value – Control Well A Value)/(Growth in Control Well A Value – Control Well A Value)  $\times 100\%$ .

(2) Percentage Inhibition of Fungal Growth = 1 – Percentage Fungal Growth.

Time-kill curves were performed according to the literature ([Li et al., 2008](#); [Sun et al., 2008](#)). *C. parapsilosis* suspensions were mixed with MAF-1A (MIC) in triplicate and cultured at  $35^{\circ}\text{C}$ . Aliquots of 100  $\mu\text{l}$  were removed from each test solution at pre-determined time points (0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 h). Dilutions were

produced (1:100) and streaked in triplicate onto SDA agar plates for colony counts after incubation at 35 °C for 24 h. Sterile ultrapure water was used as a control.

### Transcriptome sequencing

*C. parapsilosis* was inoculated into SDB medium (Sangon, Shanghai, China) at 35 °C for 24 h. *C. parapsilosis* was treated with MAF-1A at MIC for 6 h (CPAS) and 18 h (CPBS), before RNA extraction. Untreated cultures served as controls (6 h, CPAC; 18 h, CPBC). Total RNA was extracted using RNAiso Plus (Takara, Dalian, China) according to the manufacturer's instructions. RNA concentration and quality were determined on a NanoDrop 2000 (Thermo Fisher Scientific, Wilmington, DE, USA) and Agilent 2100 bioanalyzer (Agilent Technologies, CA, USA). Libraries were prepared using NEBNext® Ultra™ RNA Library Prep Kit (NEB, USA) as per the manufacturer's recommendations. Purified libraries were quantified on an Agilent 2100 bioanalyzer. Effective concentrations were determined through qRT-PCR analysis. Libraries were prepared and sequenced using a Novoseq sequencer (Illumina, USA) to produce 150 bp paired-end reads.

### Differential expression analysis


Raw reads were filtered to obtain high-quality clean reads for subsequent analysis. All reads were mapped to the reference genome of *C. parapsilosis* (assembly ASM18276v2) from the National Center for Biotechnology Information (NCBI) using HISAT2 v2.0.5 (Kim, Langmead & Salzberg, 2015). Differential expression analysis between the conditions was assessed using the Bioconductor software package DESeq2 in R 1.16.1 (Love, Huber & Anders, 2014). Relative gene expression was assessed using FPKM (Fragments Per Kilobase of transcript sequence per Millions of base pairs sequenced) and compared using log<sub>2</sub> FC. *P*-values were adjusted to generate false discovery rates (padj) as described by Benjamini-Yekutieli, assigning the significance threshold for DEGs as padj < 0.05 (Benjamini et al., 2001; Mortazavi et al., 2008).

### Enrichment and interaction network analysis of the differentially expressed genes

To further understand the functions of the DEGs, Gene Ontology (GO) enrichment was performed using the Bioconductor software clusterProfiler 3.4.4 in R package (Yu et al., 2012). Statistical enrichment of the DEGs was also performed in the Kyoto Encyclopedia of Genes and Genomes (KEGG) for pathway enrichment (Kanehisa et al., 2019; Ogata et al., 1999). PPI analysis of the DEGs was performed based on the STRING database to define key protein-protein interactions (Yu et al., 2012). The network was constructed using Cytoscape 3.6.1 (Shannon et al., 2003).

### Validation of RNA-seq by quantitative RT-PCR (qRT-PCR)

To confirm the RNA-seq data, 20 DEGs (10 with increased expression and 10 with decreased expression) were selected for qRT-PCR validations. Reactions were performed using SYBR Premix Ex Taq™ Kit (Takara) according to the manufacturer's protocol. Reaction conditions were as follows: 40 cycles of 95 °C for 30 s; 95 °C for 5 s; and 60 °C for 30 s. PCRs were performed on a BIO-RAD CFX-Connect Real-Time System. Relative gene



**Figure 1** Time-kill curves of MAF-1A under MIC for *C. parapsilosis*. The mean growth of three *C. parapsilosis* cultures were recorded (Log<sub>10</sub> CFU/ml) every 2 h for 24 h.

Full-size DOI: 10.7717/peerj.9767/fig-1

expression was determined using the  $2^{-\Delta\Delta C_t}$  method normalized to 18S rRNA (Livak & Schmittgen, 2001). Significant differences were determined using a *t*-test with a threshold of  $p < 0.05$ . Primers are listed in Table S1. Primer efficiency and melting curves are listed in Table S2 and Figs. S1–S5.


## RESULTS

### MIC assays and time-kill curves

The MIC of MAF-1A against *C. parapsilosis* was determined as 0.6 mg/mL. Time-kill curves of MAF-1A at MIC showed a gradual antifungal effect during the first 8 h of *C. parapsilosis* culture (Fig. 1). After 8 h, cell numbers increased but remained lower than those of the control group.

### Transcriptional stress responses and enrichment analysis of MAF-1A treated *C. parapsilosis*

RNA-seq analysis in *C. parapsilosis* treated with MAF-1A for 6 and 18 h showed 5,747 DEGs. Sequence reads were deposited in the NCBI Sequence Read Archive (SRA) under accession number PRJNA638006. A total of 2,439 DEGs were detected. Out of these genes, 2187 were identified at 6 h, representing 38.05% of the total detectable genes. A total of 252 genes were differentially expressed after 18 h and accounted for 4.38% of the total expressed genes. After 6 and 18 h of MAF-1A treatment, 67 DEGs with opposite trends were observed (reversed genes 1, RG1 and reversed genes 2, RG2). In total, 56 DEGs were upregulated, whilst down-regulated genes remained unchanged (one unchanged genes: UG1; two unchanged genes: UG2) (Fig. 2).



**Figure 2** Gene expression changes in *C. parapsilosis* following MAF-1A treatment. Volcano plots of the DEGs. (A) Volcano plots depicting log<sub>2</sub> FC (fold change) in expression after 6 h of treatment with MAF-1A, (C) parapsilosis was treated with MAF-1A at MIC for 6 h (CPAS), without MAF-1A as a control (CPAC). The expression of 1122 genes significantly increased; 1065 genes were significantly downregulated (padj < 0.05). (B) Volcano plot depicting the log<sub>2</sub> FC expression after 18 h of treatment with MAF-1A. (C) parapsilosis was treated with MAF-1A at MIC for 18 h (CPBS). Controls lacked MAF-1A treatment (CPBC). The expression of 101 genes significantly increased in contrast to 151 genes whose expression decreased (padj < 0.05). (C) Gene expression Venn diagrams revealing two gene groups with opposite trends, labeled as RG1, RG2, UG1 and UG2; CPAS vs. CPAC\_up: genes with increased expression after 6 h; CPAS vs. CPAC\_down: genes with decreased expression after 6 h; CPBS vs. CPBC\_up: genes with increased expression after 18 h; CPBS vs. CPBC\_down: genes with decreased expression after 18 h.

Full-size DOI: [10.7717/peerj.9767/fig-2](https://doi.org/10.7717/peerj.9767/fig-2)

### DEG enrichment analysis

Amongst the DEGs at 6 h, 1122 showing increased expression were enriched in 85 KEGG pathways, 20 of which were significant with padj < 0.05. The most significant pathways with increased expression in *C. parapsilosis* following MAF-1A treatment were: oxidative

**Table 1** Significantly enriched KEGG pathways for genes with increased expression after 6 h of MAF-1A treatment.

KEGG ID	Description	<i>p</i> value	padj
cdu00190	Oxidative phosphorylation	$3.34 \times 10^{-12}$	$2.84 \times 10^{-10}$
cdu04146	Peroxisome	$2.02 \times 10^{-8}$	$8.56 \times 10^{-7}$
cdu00020	Citrate cycle (TCA cycle)	$2.21 \times 10^{-5}$	$6.27 \times 10^{-4}$
cdu01200	Carbon metabolism	$3.50 \times 10^{-5}$	$7.44 \times 10^{-4}$
cdu04111	Cell cycle—yeast	$9.20 \times 10^{-5}$	$1.56 \times 10^{-3}$
cdu04011	MAPK signaling pathway—yeast	$8.17 \times 10^{-4}$	$1.16 \times 10^{-2}$
cdu04113	Meiosis—yeast	$2.35 \times 10^{-3}$	$2.80 \times 10^{-2}$
cdu00071	Fatty acid degradation	$2.63 \times 10^{-3}$	$2.80 \times 10^{-2}$
cdu04136	Autophagy—other	$4.03 \times 10^{-3}$	$3.80 \times 10^{-2}$

**Notes.**

padj of  $< 0.05$  set as the significance threshold.

phosphorylation, peroxisome, citrate cycle (TCA cycle), carbon metabolism, cell cycle—yeast, MAPK signaling—yeast, meiosis—yeast, fatty acid degradation, and autophagy (Table 1). Genes of decreased expression were enriched in steroid biosynthesis, biosynthesis of amino acids, cysteine and methionine metabolism, biosynthesis of antibiotics, ribosome, RNA polymerase, biosynthesis of secondary metabolites, RNA transport, ribosome biogenesis in eukaryotes, lysine biosynthesis, 2-oxocarboxylic acid metabolism, pyrimidine metabolism, glycine, serine and threonine metabolism and purine metabolism (Table 2). At 18 h, 101 genes were upregulated and enriched in 24 KEGG pathways, two of which were significant (Table 3). A total of 151 genes were downregulated and significantly enriched in carbon metabolism, biosynthesis of antibiotics, oxidative phosphorylation, the biosynthesis of secondary metabolites, and the biosynthesis of amino acids (Table 4).

**RG1, RG2, UG1, and UG2 gene enrichment analysis**

The 42 genes in RG1 were enriched in 17 KEGG pathways, of which oxidative phosphorylation was most significant. Additionally, 25 genes in RG2 were enriched in 13 KEGG pathways, of which arginine biosynthesis, the biosynthesis of antibiotics, the biosynthesis of amino acids, and the biosynthesis of secondary metabolites were enriched. A total of 24 genes in UG1 and 32 genes in UG2 were enriched in 8 and 20 KEGG pathways, respectively. In UG1, the genes were enriched in butanoate metabolism, propionate metabolism, beta-alanine metabolism, valine, leucine, and isoleucine degradation. No pathways were significantly enriched in UG2 at a padj  $< 0.05$  (Table 5).

Genes in RG1, RG2, UG1, and UG2 were enriched in 535 GO terms, a total of 9 of which were significant (Table 6). Genes in RG1 were involved in energy production and redox processes. Genes in RG2 were associated with the anabolic processes of various organic acids. Genes in UG2 were involved in oxidation–reduction processes.

**Verification of differentially expressed genes**

A total of 20 genes were selected, including 10 with increased expression and 10 with decreased expression. Genes were evenly selected from 6 h and 18 h time points to validate the RNA-seq data by qRT-PCR. The results indicated the expression levels have a

**Table 2** Significantly enriched KEGG pathways for genes with decreased expression after 6 h of MAF-1A treatment.

KEGG ID	Description	<i>p</i> value	padj
cdu00100	Steroid biosynthesis	$1.64 \times 10^{-8}$	$1.40 \times 10^{-6}$
cdu01230	Biosynthesis of amino acids	$5.95 \times 10^{-7}$	$2.53 \times 10^{-5}$
cdu00270	Cysteine and methionine metabolism	$4.80 \times 10^{-6}$	$1.36 \times 10^{-4}$
cdu01130	Biosynthesis of antibiotics	$1.07 \times 10^{-5}$	$2.27 \times 10^{-4}$
cdu03010	Ribosome	$3.01 \times 10^{-5}$	$5.12 \times 10^{-4}$
cdu03020	RNA polymerase	$2.14 \times 10^{-4}$	$3.03 \times 10^{-3}$
cdu01110	Biosynthesis of secondary metabolites	$3.68 \times 10^{-4}$	$4.47 \times 10^{-3}$
cdu03013	RNA transport	$9.34 \times 10^{-4}$	$8.83 \times 10^{-3}$
cdu03008	Ribosome biogenesis in eukaryotes	$9.35 \times 10^{-4}$	$8.83 \times 10^{-3}$
cdu00300	Lysine biosynthesis	$2.31 \times 10^{-3}$	$1.96 \times 10^{-2}$
cdu01210	2-Oxocarboxylic acid metabolism	$2.66 \times 10^{-3}$	$2.05 \times 10^{-2}$
cdu00240	Pyrimidine metabolism	$3.54 \times 10^{-3}$	$2.40 \times 10^{-2}$
cdu00260	Glycine, serine and threonine metabolism	$3.67 \times 10^{-3}$	$2.40 \times 10^{-2}$
cdu00230	Purine metabolism	$5.08 \times 10^{-3}$	$3.09 \times 10^{-2}$

**Notes.**

padj of < 0.05 set as the significance threshold.

**Table 3** Significantly enriched KEGG pathways for genes with increased expression after 18 h of MAF-1A treatment.

KEGG ID	Description	<i>p</i> -value	padj
cdu00220	Arginine biosynthesis	$3.01 \times 10^{-4}$	$7.21 \times 10^{-3}$
cdu00250	Alanine, aspartate and glutamate metabolism	$1.48 \times 10^{-3}$	$1.77 \times 10^{-2}$

**Notes.**

padj of < 0.05 were set as the significance threshold.

consistent change for both RNASeq and qRT-PCR. Hence, the qRT-PCR results confirmed the reliability of our RNA-Seq data (Fig. 3).

### Protein-protein interaction (PPI) network analysis

We constructed a PPI network based on the STRING database of the DEGs after 6 h of treatment. The PPI network contained 624 nodes and 6264 edges, with a degree filter of  $\geq 10$  (Fig. 4). The connectivity degree (dg) of multiple nodes in the PPI network were high, including: CpUbi1 (dg = 146), CpGlt1 (dg = 82), CpCdc28 (dg = 54), CpCys4 (dg = 50), CpCyt1 (dg = 45), CpRpc40 (dg = 42), CpArx1 (dg = 42), CpDim1 (dg = 41), CpYtm1 (dg = 41), CpRip1 (dg = 41). Upon enrichment analyses the identified genes were associated with oxidative phosphorylation (Fig. S6).

## DISCUSSION

*C. parapsilosis* is one of the most prevalent fungal species in many regions. In addition to its high rates of infection, its etiology differs from that of *C. albicans* (Holland et al., 2014). Specific *C. parapsilosis* isolates are resistant to conventional antifungal drugs including echinocandins, azoles, and amphotericin B (Lotfali et al., 2016; Maria et al., 2018; Thomaz et al., 2018). Antimicrobial peptides lead to cell lysis and death through



**Table 4** Significantly enriched KEGG pathways for genes with decreased expression after 18 h of MAF-1A treatment.

KEGG ID	Description	<i>p</i> -value	<i>padj</i>
cdu01200	Carbon metabolism	$1.65 \times 10^{-8}$	$7.61 \times 10^{-7}$
cdu01130	Biosynthesis of antibiotics	$6.21 \times 10^{-7}$	$1.43 \times 10^{-5}$
cdu00190	Oxidative phosphorylation	$5.58 \times 10^{-6}$	$6.91 \times 10^{-5}$
cdu01110	Biosynthesis of secondary metabolites	$6.01 \times 10^{-6}$	$6.91 \times 10^{-5}$
cdu00010	Glycolysis/Gluconeogenesis	$1.71 \times 10^{-5}$	$1.57 \times 10^{-4}$
cdu00260	Glycine, serine and threonine metabolism	$5.83 \times 10^{-4}$	$4.47 \times 10^{-3}$
cdu01230	Biosynthesis of amino acids	$1.77 \times 10^{-3}$	$1.16 \times 10^{-2}$
cdu00680	Methane metabolism	$3.62 \times 10^{-3}$	$2.05 \times 10^{-2}$
cdu00520	Amino sugar and nucleotide sugar metabolism	$4.02 \times 10^{-3}$	$2.05 \times 10^{-2}$
cdu00052	Galactose metabolism	$6.24 \times 10^{-3}$	$2.87 \times 10^{-2}$
cdu00730	Thiamine metabolism	$7.93 \times 10^{-3}$	$3.20 \times 10^{-2}$
cdu00630	Glyoxylate and dicarboxylate metabolism	$8.34 \times 10^{-3}$	$3.20 \times 10^{-2}$
cdu00330	Arginine and proline metabolism	$9.61 \times 10^{-3}$	$3.24 \times 10^{-2}$
cdu00670	One carbon pool by folate	$9.85 \times 10^{-3}$	$3.24 \times 10^{-2}$

**Notes.**

*padj* of < 0.05 set as the significance threshold.

**Table 5** Significantly enriched KEGG pathways for genes in RG1, RG2 and UG1.

Sort	KEGG ID	Description	<i>p</i> -value	<i>padj</i>
RG1	cdu00190	Oxidative phosphorylation	$1.34 \times 10^{-5}$	$2.27 \times 10^{-4}$
RG2	cdu00220	Arginine biosynthesis	$1.97 \times 10^{-5}$	$2.56 \times 10^{-4}$
	cdu01130	Biosynthesis of antibiotics	$4.09 \times 10^{-3}$	$2.39 \times 10^{-2}$
	cdu01230	Biosynthesis of amino acids	$5.52 \times 10^{-3}$	$2.39 \times 10^{-2}$
	cdu01110	Biosynthesis of secondary metabolites	$1.21 \times 10^{-2}$	$3.92 \times 10^{-2}$
UG1	cdu00650	Butanoate metabolism	$1.82 \times 10^{-2}$	$4.91 \times 10^{-2}$
	cdu00640	Propanoate metabolism	$2.48 \times 10^{-2}$	$4.91 \times 10^{-2}$
	cdu00410	beta-Alanine metabolism	$2.64 \times 10^{-2}$	$4.91 \times 10^{-2}$
	cdu00280	Valine, leucine and isoleucine degradation	$2.81 \times 10^{-2}$	$4.91 \times 10^{-2}$

**Notes.**

*padj* of < 0.05 set as the significance threshold.

cell membrane leakage (Papo & Shai, 2003; Paterson et al., 2017; Shai, 1999; Utesch et al., 2018). However, mechanistic studies of antimicrobial peptides have determined that their membrane interactions are complex. Park, Kim & Kim (1998) showed that buforin II prevents microorganisms entry into cells. Lee et al. (2019) found that antifungal  $\beta$ -peptides cause cell death by entering cells and causing nuclear and vacuole dysfunction. Chileveru et al. (2015) showed that human alpha-defensin 5 enters the cytoplasm of Escherichia coli and interferes with cell division.

AMPs work through various mechanisms. In our previous studies, we showed that MAF-1A inhibits *C. albicans* through its effects on the cell wall, cell membrane, and ribosomes (Wang et al., 2017). In this study, we found that MAF-1A alters gene expression in several important biological pathways in *C. parapsilosis*, including oxidation–reduction

**Table 6** Significant enriched GO terms of RG1, RG2 and UG2.

Sort	Category	GO ID	Description	p-value	padj
RG1	BP	GO:0006091	Generation of precursor metabolites and energy	$8.71 \times 10^{-5}$	$7.14 \times 10^{-3}$
	BP	GO:0055114	Oxidation–reduction process	$8.49 \times 10^{-4}$	$3.48 \times 10^{-2}$
RG2	BP	GO:0016053	Organic acid biosynthetic process	$5.27 \times 10^{-4}$	$2.11 \times 10^{-2}$
	BP	GO:0046394	Carboxylic acid biosynthetic process	$5.27 \times 10^{-4}$	$2.11 \times 10^{-2}$
	BP	GO:0044283	Small molecule biosynthetic process	$1.56 \times 10^{-3}$	$3.12 \times 10^{-2}$
	BP	GO:0006082	Organic acid metabolic process	$2.34 \times 10^{-3}$	$3.12 \times 10^{-2}$
	BP	GO:0019752	Carboxylic acid metabolic process	$2.34 \times 10^{-3}$	$3.12 \times 10^{-2}$
	BP	GO:0043436	Oxoacid metabolic process	$2.34 \times 10^{-3}$	$3.12 \times 10^{-2}$
UG2	BP	GO:0055114	Oxidation–reduction process	$3.53 \times 10^{-4}$	$2.15 \times 10^{-2}$


**Notes.**

padj of  $< 0.05$  set as the significance threshold for enrichment.

processes and alternative energy sources. We further compared the response of *C. albicans* and *C. parapsilosis* to MAF-1A, most DEGs have the same expression trend (upregulated/downregulated), and identified changes in both stress and energy metabolism pathways (carbon metabolism, cell cycle, peroxisome, carbon metabolism, fatty acid degradation) (Tables S3 and S4). We hypothesized that the antifungal peptide MAF-1A exerts antifungal effect and disrupts energy metabolism by affecting oxidation–reduction processes, due to its effects on the mitochondria. Whilst antimicrobial peptides have multiple modes of action, these remain undetermined for MAF-1A. Our findings suggest that intracellular targets may be the key sites of MAF-1A activity, with enrichment analysis of the DEGs suggesting that MAF-1A exerts antimicrobial activity through a variety of mechanisms.

**Membrane destruction**

Genes with decreased expression after 6 h were significantly enriched in steroid biosynthesis (Fig. 5) including *CpERG1*, *CpERG3*, *CpERG6*, *CpERG7*, *CpERG9*, *CpERG11*, *CpERG25*, *CpERG26*, *CpERG27*, *CpERG2*, *CpERG4*, *CpERG5*, *CpERG24*, and *CpSPBC16A3.12c* (Kanehisa et al., 2019; Ogata et al., 1999). Azole agents exert antifungal activity by inhibiting the synthesis of ergosterol, a major component of fungal cell membranes (Ermakova & Zuev, 2017). The overexpression of *ERG11* (encoding lanosterol 14-demethylase) is a major cause of azole resistance, often mediated by point mutations in the *ERG11* gene. Members of the *ERG* gene family encode proteins involved in ergosterol biosynthesis, of which lanosterol 14-demethylase is critical. In this study, MAF-1A decreased the expression of 14 genes related to sterol synthesis including *CpERG11*, suggesting it interferes with ergosterol synthesis. Additionally, 10 genes showed increased expression after 6 h and were enriched in fatty acid degradation pathways (Fig. 6) (Kanehisa et al., 2019; Ogata et al., 1999). Of these, the expression of *CpPOX4* (CPAR2-807700) significantly increased, ( $\log_2$  FC = 1.503). We further verified the upregulation of these genes through qRT-PCR ( $\log_2$ FC = 2.834). *CpPOX4* encodes a component of fatty acid biosynthesis, which indicates that the composition of the cell membrane was affected by MAF-1A.




**Figure 3** Validation of the RNA-seq data via qRT-PCR analysis. (A) 6 h timepoint. (B) 18 hour timepoint. \*  $p < 0.05$ , \*\*  $p < 0.01$ , ns, not-significant.

Full-size DOI: [10.7717/peerj.9767/fig-3](https://doi.org/10.7717/peerj.9767/fig-3)

### Mitochondrial function

A total of 42 genes showed increased expression at 6 h and were enriched in oxidative phosphorylation pathways. The genes were mainly involved in respiratory chain electron transport processes in the mitochondrial inner membrane, including NHD release of H<sup>+</sup> and ATP synthase (Fig. 7) (Kanehisa et al., 2019; Ogata et al., 1999). A total of six genes




**Figure 4** PPI network of the DEGs following MAF-1A treatment of *C. parapsilosis* for 6 h. Node sizes correlate with node importance; purple nodes denote genes with increased expression, and blue denote decreased expression genes.

Full-size  DOI: [10.7717/peerj.9767/fig-4](https://doi.org/10.7717/peerj.9767/fig-4)

in RG1 were also enriched in this pathway (*CpCOX15*, *Cpnuo-21*, *CpQCR2*, *CpQCR8*, *CpQCR7*, and *CpCOR1*). Previous studies showed that *COX15* encodes an indispensable mitochondrial protein for *Saccharomyces cerevisiae* cytochrome oxidase (*Glerum et al., 1997*). Cytochrome oxidase is a terminal enzyme in the respiratory electron transport chain that is essential for ATP synthesis. Reactive oxygen species (ROS) are produced by the oxidative phosphorylation of ATP and can disrupt the electron transport chain in mitochondria (*Piippo et al., 2018*). ROS production induces damage to lipids, proteins, lipids, and nucleic acids, leading to cell death. Eukaryotes prevent cell damage through oxidative stress detoxification and the prevention of ROS accumulation. In this study, GO enrichment analysis of the RG1 genes showed that 7 that were highly expressed were associated with redox processes (*CpPOX9*, *CpCOX15*, *Cpnuo-21*, *CpAAEL001134*, *CpQCR7*, *CpRGI1*, and *Cpnama*). These processes help cells to remove accumulated ROS. Due to the increased expression of these genes in response to MAF-1A, it is possible that MAF-1A promotes oxidative phosphorylation, which disrupts electron transfer in the mitochondria, enhancing ROS production and subsequent cell damage.

*C. parapsilosis* has an unusual mitochondrial genome architecture, consisting of linear DNA molecules of 30.9-Kbp, terminating with specific telomeric structures on both sides (738-Kbp long). This differs from telomeres at the ends of eukaryotic nuclear chromosomes, particularly in humans (*Kovac, Lazowska & Slonimski, 1984*). MAF-1A interferes with the expression of multiple genes related to the mitochondrial functions of *C. parapsilosis*. It is, therefore, feasible that MAF-1A interferes with the normal function of *C. parapsilosis* mitochondria.




**Figure 5** Significantly enriched KEGG pathways in steroid biosynthesis. DEGs with decreased expression are shown in blue. Permission for publication granted by the Kyoto Encyclopedia of Genes and Genomes, Kyoto University, Japan.

Full-size DOI: 10.7717/peerj.9767/fig-5

## CONCLUSIONS

In summary, MAF-1A has a complex response in *C. parapsilosis*. Most DEGs identified through RNA-seq analysis were related to oxidation–reduction processes and the use of alternative energy sources, Mitochondria are important target for the anti-fungal peptide MAF-1A to exert anti-*C. parapsilosis*. RNA-seq data therefore provide future direction to study the antifungal mechanisms of MAF-1A and highlight the potential pathways that contribute to resistance.



**Figure 6** Significantly enriched KEGG pathways in fatty acid degradation. DEGs with increased expression are marked in purple. Permission for publication was granted by the Kyoto Encyclopedia of Genes and Genomes, Kyoto University, Japan.

Full-size [DOI: 10.7717/peerj.9767/fig-6](https://doi.org/10.7717/peerj.9767/fig-6)

## ADDITIONAL INFORMATION AND DECLARATIONS

### Funding

This work was supported by the Science and Technology Department of Gui Zhou Province ((2019)2827, (2015)4015, (2018)5706); Doctoral Foundation of Guizhou Provincial People's Hospital (GZSYBS(2015)12); Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2019PT320003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


### Grant Disclosures

The following grant information was disclosed by the authors:

Science and Technology Department of Gui Zhou Province: (2019)2827, (2015)4015, (2018)5706.

Doctoral Foundation of Guizhou Provincial People's Hospital: GZSYBS(2015)12.

Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences: 2019PT320003.



**Figure 7** Significantly enriched KEGG pathways in oxidative phosphorylation. DEGs with increased expression are marked in purple. Permission for publication was granted by the Kyoto Encyclopedia of Genes and Genomes, Kyoto University, Japan.

Full-size DOI: [10.7717/peerj.9767/fig-7](https://doi.org/10.7717/peerj.9767/fig-7)

## Competing Interests

The authors declare there are no competing interests.

## Author Contributions

- Rong Cheng and Zhenhua Luo conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Wei Li performed the experiments, prepared figures and/or tables, and approved the final draft.
- Klarke M. Sample conceived and designed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
- Qiang Xu performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
- Lin Liu, Fuxun Yu and Yingjie Nie analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
- Xiangyan Zhang conceived and designed the experiments, prepared figures and/or tables, and approved the final draft.

## Data Availability

The following information was supplied regarding data availability:

The raw data are available in the [Supplementary File](#).

## Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.9767#supplemental-information>.

## REFERENCES

- Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. 2001.** Controlling the false discovery rate in behavior genetics research. *Behavioural Brain Research* **125**:279–284.
- Chileveru HR, Lim SA, Chairatana P, Wommack AJ, Chiang IL, Nolan EM. 2015.** Visualizing attack of *Escherichia coli* by the antimicrobial peptide human defensin 5. *Biochemistry* **54**:1767–1777 DOI [10.1021/bi501483q](https://doi.org/10.1021/bi501483q).
- Ermakova E, Zuev Y. 2017.** Effect of ergosterol on the fungal membrane properties. All-atom and coarse-grained molecular dynamics study. *Chemistry and Physics of Lipids* **209**:45–53 DOI [10.1016/j.chemphyslip.2017.11.006](https://doi.org/10.1016/j.chemphyslip.2017.11.006).
- Fais R, Di Luca M, Rizzato C, Morici P, Bottai D, Tavanti A, Lupetti A. 2017.** The N-terminus of human lactoferrin displays anti-biofilm activity on candida parapsilosis in lumen catheters. *Frontiers in Microbiology* **8**:Article 2218 DOI [10.3389/fmicb.2017.02218](https://doi.org/10.3389/fmicb.2017.02218).
- Fu P, Wu J, Guo G. 2009.** Purification and molecular identification of an antifungal peptide from the hemolymph of *Musca domestica* (housefly). *Cellular & Molecular Immunology* **6**:245–251 DOI [10.1038/cmi.2009.33](https://doi.org/10.1038/cmi.2009.33).
- Ghosh C, Sarkar P, Issa R, Haldar J. 2019.** Alternatives to conventional antibiotics in the era of antimicrobial resistance. *Trends in Microbiology* **27**:323–338 DOI [10.1016/j.tim.2018.12.010](https://doi.org/10.1016/j.tim.2018.12.010).
- Glerum DM, Muroff I, Jin C, Tzagoloff A. 1997.** COX15 codes for a mitochondrial protein essential for the assembly of yeast cytochrome oxidase. *Journal of Biological Chemistry* **272**:19088–19094 DOI [10.1074/jbc.272.30.19088](https://doi.org/10.1074/jbc.272.30.19088).
- Guilhelmelli F, Vilela N, Albuquerque P, Derengowski Lda S, Silva-Pereira I, Kyaw CM. 2013.** Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. *Frontiers in Microbiology* **4**:Article 353 DOI [10.3389/fmicb.2013.00353](https://doi.org/10.3389/fmicb.2013.00353).
- Holland LM, Schroder MS, Turner SA, Taff H, Andes D, Grozer Z, Gacser A, Ames L, Haynes K, Higgins DG, Butler G. 2014.** Comparative phenotypic analysis of the major fungal pathogens *Candida parapsilosis* and *Candida albicans*. *PLOS Pathogens* **10**:e1004365 DOI [10.1371/journal.ppat.1004365](https://doi.org/10.1371/journal.ppat.1004365).
- Huber A, Galgóczy L, Váradi G, Holzknicht J, Kakar A, Malanovic N, Leber R, Koch J, Keller MA, Batta G, Tóth GK, Marx F. 2020.** Two small, cysteine-rich and cationic antifungal proteins from *Penicillium chrysogenum*: a comparative study of PAF and PAFB. *Biochimica et Biophysica Acta—Biomembranes* **1862**(8):Article 183246 DOI [10.1016/j.bbamem.2020.183246](https://doi.org/10.1016/j.bbamem.2020.183246).
- Iracane E., Donovan PD., Ola M., Butler G., Holland LM.. 2018.** Identification of an exceptionally long intron in the HAC1 gene of *Candida parapsilosis*. *mSphere* **3**(6):e00532–18.



- Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M. 2019. New approach for understanding genome variations in KEGG. *Nucleic Acids Research* 47:D590–D595 DOI 10.1093/nar/gky962.
- Kim D, Langmead B, Salzberg SL. 2015. HISAT: a fast spliced aligner with low memory requirements. *Nature Methods* 12:357–360 DOI 10.1038/nmeth.3317.
- Kobbi S, Nedjar N, Chihib N, Balti R, Chevalier M, Silvain A, Chaabouni S, Dhulster P, Bougateg A. 2018. Synthesis and antibacterial activity of new peptides from Alfalfa RuBisCO protein hydrolysates and mode of action via a membrane damage mechanism against *Listeria innocua*. *Microbial Pathogenesis* 115:41–49 DOI 10.1016/j.micpath.2017.12.009.
- Kovac L, Lazowska J, Slonimski P. 1984. A yeast with linear molecules of mitochondrial DNA. *Molecular and General Genetics* 197:420–424.
- Lee MR, Raman N, Ortiz-Bermudez P, Lynn DM, Palecek SP. 2019. 14-helical beta-peptides elicit toxicity against *C. albicans* by forming pores in the cell membrane and subsequently disrupting intracellular organelles. *Cell Chemical Biology* 26:289–299. e284 DOI 10.1016/j.chembiol.2018.11.002.
- Li L, Song F, Sun J, Tian X, Xia S, Le G. 2016. Membrane damage as first and DNA as the secondary target for anti-candidal activity of antimicrobial peptide P7 derived from cell-penetrating peptide ppTG20 against *Candida albicans*. *Journal of Peptide Science* 22:427–433 DOI 10.1002/psc.2886.
- Li Y, Sun S, Guo Q, Ma L, Shi C, Su L, Li H. 2008. In vitro interaction between azoles and cyclosporin A against clinical isolates of *Candida albicans* determined by the checkerboard method and time-kill curves. *Journal of Antimicrobial Chemotherapy* 61:577–585 DOI 10.1093/jac/dkm493.
- Lis M, Liu TT, Barker KS, Rogers PD, Bobek LA. 2010. Antimicrobial peptide MUC7 12-mer activates the calcium/calmodulin pathway in *Candida albicans*. *FEMS Yeast Research* 10:579–586 DOI 10.1111/j.1567-1364.2010.00638.x.
- Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the  $2(-\Delta\Delta C(T))$  Method. *Methods* 25:402–408 DOI 10.1006/meth.2001.1262.
- Lotfali E, Kordbacheh P, Mirhendi H, Zaini F, Ghajari A, Mohammadi R, Noorbakhsh F, Moazeni M, Fallahi A, Rezaie S. 2016. Antifungal susceptibility analysis of clinical isolates of *Candida parapsilosis* in Iran. *Iranian Journal of Public Health* 45:322–328.
- Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biology* 15:Article 550 DOI 10.1186/s13059-014-0550-8.
- Maria S, Barnwal G, Kumar A, Mohan K, Vinod V, Varghese A, Biswas R. 2018. Species distribution and antifungal susceptibility among clinical isolates of *Candida parapsilosis* complex from India. *Revista Iberoamericana de Micología* 35:147–150 DOI 10.1016/j.riam.2018.01.004.
- Moravej H, Moravej Z, Yazdanparast M, Heiat M, Mirhosseini A, Moosazadeh Moghaddam M, Mirnejad R. 2018. Antimicrobial peptides: features, action, and

- their resistance mechanisms in bacteria. *Microbial Drug Resistance* **24**:747–767 DOI [10.1089/mdr.2017.0392](https://doi.org/10.1089/mdr.2017.0392).
- Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. 2008.** Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nature Methods* **5**:621–628 DOI [10.1038/nmeth.1226](https://doi.org/10.1038/nmeth.1226).
- Nuti R, Goud NS, Saraswati AP, Alvala R, Alvala M. 2017.** Antimicrobial peptides: a promising therapeutic strategy in tackling antimicrobial resistance. *Current Medicinal Chemistry* **24**:4303–4314 DOI [10.2174/0929867324666170815102441](https://doi.org/10.2174/0929867324666170815102441).
- Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. 1999.** KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Research* **27**:29–34 DOI [10.1093/nar/27.1.29](https://doi.org/10.1093/nar/27.1.29).
- Papo N, Shai Y. 2003.** Exploring peptide membrane interaction using surface plasmon resonance: differentiation between pore formation versus membrane disruption by lytic peptides. *Biochemistry* **42**:458–466 DOI [10.1021/bi0267846](https://doi.org/10.1021/bi0267846).
- Park CB, Kim HS, Kim SC. 1998.** Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. *Biochemical and Biophysical Research Communications* **244**:253–257 DOI [10.1006/bbrc.1998.8159](https://doi.org/10.1006/bbrc.1998.8159).
- Paterson DJ, Tassieri M, Reboud J, Wilson R, Cooper JM. 2017.** Lipid topology and electrostatic interactions underpin lytic activity of linear cationic antimicrobial peptides in membranes. *Proceedings of the National Academy of Sciences of the United States of America* **114**:E8324–E8332 DOI [10.1073/pnas.1704489114](https://doi.org/10.1073/pnas.1704489114).
- Patocka J, Nepovimova E, Klimova B, Wu Q, Kuca K. 2018.** Antimicrobial peptides: amphibian host defense peptides. *Current Medicinal Chemistry* **26**(32):5924–5946 DOI [10.2174/0929867325666180713125314](https://doi.org/10.2174/0929867325666180713125314).
- Piippo N, Korhonen E, Hytti M, Kinnunen K, Kaarniranta K, Kauppinen A. 2018.** Oxidative stress is the principal contributor to inflammasome activation in retinal pigment epithelium cells with defunct proteasomes and autophagy. *Cellular Physiology and Biochemistry* **49**:359–367 DOI [10.1159/000492886](https://doi.org/10.1159/000492886).
- Robbins N, Caplan T, Cowen LE. 2017.** Molecular evolution of antifungal drug resistance. *Annual Review of Microbiology* **71**:753–775 DOI [10.1146/annurev-micro-030117-020345](https://doi.org/10.1146/annurev-micro-030117-020345).
- Shai Y. 1999.** Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. *Biochimica et Biophysica Acta/General Subjects* **1462**:55–70.
- Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. 2003.** Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Research* **13**:2498–2504 DOI [10.1101/gr.1239303](https://doi.org/10.1101/gr.1239303).
- Sular FL, Szekely E, Cristea VC, Dobreanu M. 2018.** Invasive fungal infection in Romania: changing incidence and epidemiology during six years of surveillance in a tertiary hospital. *Mycopathologia* **183**:967–972 DOI [10.1007/s11046-018-0293-2](https://doi.org/10.1007/s11046-018-0293-2).

- Sun S, Li Y, Guo Q, Shi C, Yu J, Ma L. 2008.** In vitro interactions between tacrolimus and azoles against *Candida albicans* determined by different methods. *Antimicrobial Agents and Chemotherapy* 52:409–417 DOI [10.1128/AAC.01070-07](https://doi.org/10.1128/AAC.01070-07).
- Thomaz DY, De Almeida Jr JN, Lima GME, Nunes MO, Camargo CH, Grenfell RC, Benard G, Negro GMBDel. 2018.** An azole-resistant *Candida parapsilosis* outbreak: clonal persistence in the intensive care unit of a Brazilian teaching hospital. *Frontiers in Microbiology* 9:Article 2997 DOI [10.3389/fmicb.2018.02997](https://doi.org/10.3389/fmicb.2018.02997).
- Toth R, Nosek J, Mora-Montes HM, Gabaldon T, Bliss JM, Nosanchuk JD, Turner SA, Butler G, Vagvolgyi C, Gacser A. 2019.** *Candida parapsilosis*: from genes to the bedside. *Clinical Microbiology Reviews* 32(2):e00111–18 DOI [10.1128/cmr.00111-18](https://doi.org/10.1128/cmr.00111-18).
- Utesch T, De Miguel Catalina A, Schattenberg C, Paegle N, Schmieder P, Krause E, Miao Y, McCammon JA, Meyer V, Jung S, Mroginski MA. 2018.** A computational modeling approach predicts interaction of the antifungal protein AFP from *Aspergillus giganteus* with fungal membranes via its gamma-core motif. *mSphere* 3:e00377–18 DOI [10.1128/mSphere.00377-18](https://doi.org/10.1128/mSphere.00377-18).
- Vieira de Melo AP, Zuza-Alves DL, Da Silva-Rocha WP, Ferreira Canario de Souza LB, Francisco EC, Salles de Azevedo Melo A, Maranhao Chaves G. 2019.** Virulence factors of *Candida* spp. obtained from blood cultures of patients with candidemia attended at tertiary hospitals in Northeast Brazil. *Journal de Mycologie Medicale* 29(2):132–139 DOI [10.1016/j.mycmed.2019.02.002](https://doi.org/10.1016/j.mycmed.2019.02.002).
- Wang T, Xiu J, Zhang Y, Wu J, Ma X, Wang Y, Guo G, Shang X. 2017.** Transcriptional responses of *Candida albicans* to antimicrobial peptide MAF-1A. *Frontiers in Microbiology* 8:Article 894 DOI [10.3389/fmicb.2017.00894](https://doi.org/10.3389/fmicb.2017.00894).
- Yu G, Wang LG, Han Y, He QY. 2012.** clusterProfiler: an R package for comparing biological themes among gene clusters. *OmicS* 16:284–287 DOI [10.1089/omi.2011.0118](https://doi.org/10.1089/omi.2011.0118).
- Zhou J, Kong L, Fang N, Mao B, Ai H. 2016.** Synthesis and functional characterization of maf-1a peptide derived from the larvae of housefly, *Musca domestica* (Diptera: Muscidae). *Journal of Medical Entomology* 53:1467–1472 DOI [10.1093/jme/tjw110](https://doi.org/10.1093/jme/tjw110).